105355-35-9

Upstream product

• 350-46-9 4-Fluoronitrobenzene 
• 105355-30-4 Methyl 2-bromo-3-<4-<2-(5-methyl-2-pyridyl)ethoxy>phenyl>propionate 
• 85583-51-3 4-[2-(5-methyl-pyridin-2-yl)ethoxy]nitrobenzene 
• 85583-37-5 4-[2-(5-methyl-pyridin-2-yl)ethoxy]aniline 
• 71858-91-8 2-(5-methyl-[2]pyridyl)-ethanol 
• 105355-32-6 2-imino-5-{4-[2-(5-methyl-pyridin-2-yl)ethoxy]benzyl}-4-thiazolidinone 

Relevant academic research and scientific papers

Pyridine N-oxide compounds which are useful as hypoglycemic and hypolipidemic agents

There is disclosed a novel thiazolidinedione derivative of the general formula (I): STR1 wherein R1 and R2 are the same or different and are a hydrogen atom or a lower alkyl group, or a salt thereof. The thiazolidinedione derivative has hypoglycemic activity and hypolipidemic activity.

Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones

The synthesis of a series of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones is described. These compounds were evaluated for hypoglycemic and hypolipidemic activities in genetically obese and diabetic mice, yellow KK. 2-(2-Pyridyl)alkoxy derivatives were found to have much better hypoglycemic and hypolipidemic activities than 2-(3-pyridyl)- and 2-(4-pyridyl)alkoxy derivatives or even the previously reported compound, ciglitazone. The introduction of a hydroxyl group at the 2-position of the ethoxy chain potentiated the activities. Among the potent compounds, pioglitazone (AD-4833) was selected as a candidate compound.

Thiazolidinedione derivatives, useful as antidiabetic agents

Thiazolidinedione derivatives of the formula: STR1 and pharmacologically acceptable salts thereof are novel compounds, which exhibit in mammals blood sugar- and lipid-lowering activity, and are of value as a therapeutic agent for treatment of diabetes and hyperlipemia.